Vets Who Took Paxlovid Less Likely to Get Long COVID, VA Study Finds
Headline from Military.com
An analysis of more than 56,000 veterans infected with COVID-19 found that those treated with the new Pfizer drug had a 26% reduction in the risk of developing long COVID.
Military.com's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
An analysis of more than 56,000 veterans infected with COVID-19 found that those treated with the new Pfizer drug had a 26% reduction in the risk of developing long COVID.
The research looked at patients who qualified for the antiviral through age or health conditions. Those who took it shortly after infection were 26 percent less likely to have symptoms 90 days later.
The antiviral pill Paxlovid not only reduces hospitalization and death after catching COVID-19: New research shows it also cuts the chances of long COVID by roughly 25%.
MONDAY, Nov. 7, 2022 (HealthDay News) -- The antiviral pill Paxlovid not only reduces hospitalization and death after catching COVID-19: New research shows it also cuts the chances of long
Paxlovid, the antiviral pill that reduces the risk of hospitalization and death from COVID-19, also reduces the risk of long COVID-19, according to a new study by researchers at the US Department of Veterans Affairs.
A new study offers some hope for a treatment of long Covid. Paxlovid, the antiviral pill that reduces the risk of hospitalization and death from Covid-19, also reduces the risk of long Covid, according to a new study by researchers at the US Department of Veterans Affairs.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
Vets Who Took Paxlovid Less Likely to Get Long COVID, VA Study Finds | Since Then
